JP2963720B2 - 記憶および学習憎進または認知もしくは精神障害治療用のｄ―シクロセリンおよびｄ―アラニン含有組成物 - Google Patents

記憶および学習憎進または認知もしくは精神障害治療用のｄ―シクロセリンおよびｄ―アラニン含有組成物

Info

Publication number
JP2963720B2
JP2963720B2 JP2063937A JP6393790A JP2963720B2 JP 2963720 B2 JP2963720 B2 JP 2963720B2 JP 2063937 A JP2063937 A JP 2063937A JP 6393790 A JP6393790 A JP 6393790A JP 2963720 B2 JP2963720 B2 JP 2963720B2
Authority
JP
Japan
Prior art keywords
cycloserine
alanine
glycine
memory
learning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2063937A
Other languages
English (en)
Japanese (ja)
Other versions
JPH03148221A (ja
Inventor
エイ．コーディ アレクシス
アール ジャンズ マイクル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of JPH03148221A publication Critical patent/JPH03148221A/ja
Application granted granted Critical
Publication of JP2963720B2 publication Critical patent/JP2963720B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Medicinal Preparation (AREA)
JP2063937A 1989-03-15 1990-03-14 記憶および学習憎進または認知もしくは精神障害治療用のｄ―シクロセリンおよびｄ―アラニン含有組成物 Expired - Lifetime JP2963720B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32427989A 1989-03-15 1989-03-15
US324279 1989-03-15
US473241 1990-02-06
US07/473,241 US5061721A (en) 1989-03-15 1990-02-06 Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Publications (2)

Publication Number Publication Date
JPH03148221A JPH03148221A (ja) 1991-06-25
JP2963720B2 true JP2963720B2 (ja) 1999-10-18

Family

ID=26984373

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2063937A Expired - Lifetime JP2963720B2 (ja) 1989-03-15 1990-03-14 記憶および学習憎進または認知もしくは精神障害治療用のｄ―シクロセリンおよびｄ―アラニン含有組成物

Country Status (17)

Country Link
US (1) US5061721A (Direct)
EP (1) EP0387867B1 (Direct)
JP (1) JP2963720B2 (Direct)
KR (1) KR900013961A (Direct)
AT (1) ATE88890T1 (Direct)
AU (1) AU624917B2 (Direct)
CA (1) CA2010635C (Direct)
DE (1) DE69001503T2 (Direct)
DK (1) DK0387867T3 (Direct)
ES (1) ES2055197T3 (Direct)
FI (1) FI901289A7 (Direct)
GR (1) GR3008225T3 (Direct)
IE (1) IE64130B1 (Direct)
IL (1) IL93562A (Direct)
NO (1) NO901198L (Direct)
NZ (1) NZ232809A (Direct)
PT (1) PT93424B (Direct)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
ATE311864T1 (de) * 1993-03-29 2005-12-15 Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable salze zur behandlung von amyloidosis
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
WO1996015788A1 (en) * 1994-11-23 1996-05-30 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
ATE204852T1 (de) * 1995-02-15 2001-09-15 Bearsden Bio Inc Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
JP2001507924A (ja) 1996-07-22 2001-06-19 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション コナントキン類
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
WO1998003189A1 (en) 1996-07-22 1998-01-29 Cognetix, Inc. Use of conantokins
CA2601132C (en) * 1998-04-14 2011-11-08 The General Hospital Corporation Use of n-methylglycine and pharmaceutical compositions comprising n-methylglycine for treating neuropsychiatric disorders
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
AU2002311784B2 (en) * 2001-03-29 2007-11-22 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
JP2004527520A (ja) * 2001-04-02 2004-09-09 パノラマ リサーチ，インコーポレイティド 治療剤としての抗酸化ニトロキシドおよびニトロン
WO2002087423A2 (en) * 2001-05-02 2002-11-07 Blanchette Rockefeller Neurosciences Institute Carbonic anhydrase activators for enhancing learning and memory
EP1487542A1 (en) * 2002-03-15 2004-12-22 H. Lundbeck A/S Use of asc-1 inhibitors to treat neurological and psychiatric disorders
KR20070104480A (ko) * 2003-05-27 2007-10-25 포레스트 래보러토리즈, 인코포레이티드 우울증 및 그 밖의 기분장애의 치료를 위한 ｎｍｄａ수용체 길항제 및 선택적 세로토닌 재흡수 억제제의 배합물
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
EP1660634A4 (en) * 2003-08-08 2009-02-18 Burnham Inst P16-mediated regulation of NMDA receptors
CA2592631A1 (en) 2003-12-29 2005-07-21 Jason Mcdevitt Compositions and methods to treat recurrent medical conditions
TW201207390A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Method for screening agent for antidepressant activity
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2592320C (en) 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
MX2007012374A (es) * 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
ES2533463T3 (es) 2006-10-12 2015-04-10 Bhi Limited Partnership Métodos, compuestos, composiciones y vehículos para suministrar ácido 3-amino-1-propanosulfónico
US20100113453A1 (en) * 2007-04-10 2010-05-06 Mcdevitt Jason P Sublingual Formulations of D-Cycloserine and Methods of Using Same
BRPI0918868B8 (pt) 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
TWI544923B (zh) * 2009-12-29 2016-08-11 何應瑞 用於治療神經退化性疾病之醫藥組合物
EP2542254B1 (en) 2010-02-11 2018-09-26 Northwestern University Nmda receptor agonists and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
JP5689026B2 (ja) * 2010-06-17 2015-03-25 株式会社 資生堂 水中油型乳化皮膚化粧料
EP2670409B1 (en) * 2011-01-31 2018-04-18 Serotech, LLC Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
WO2014093277A1 (en) 2012-12-11 2014-06-19 The Mclean Hospital Corporation Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
WO2014120789A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2015009773A (es) 2013-01-29 2016-08-05 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
LT3514158T (lt) 2013-01-29 2023-02-10 Aptinyx Inc. Spirolaktaminiai nmda receptoriaus moduliatoriai ir jų panaudojimas
SG11201505862TA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
PE20151427A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
KR102128675B1 (ko) 2016-05-19 2020-06-30 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
IL286107B2 (en) 2016-08-01 2024-09-01 Aptinyx Inc Spiro-lactam nmda receptor modulators and usesthereof
AU2017306164B2 (en) 2016-08-01 2021-10-21 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam NMDA modulators and methods of using same
WO2018026792A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
EP3490974B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
SG10202101055VA (en) 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
JP7210599B2 (ja) 2018-01-31 2023-01-23 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
WO2020252384A1 (en) * 2019-06-14 2020-12-17 Vorsanger Gary Treatment methods utilizing oxytocin receptor agonists
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
CN114786668B (zh) 2019-11-27 2024-07-16 诺罗瑞韦有限公司 用于治疗抑郁症的环丝氨酸和锂的组合疗法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428730A (en) * 1967-06-30 1969-02-18 Hamao Umezawa Antibacterial mixture of o-carbamyl-d-serine and d-4-amino-3-isoxazolidone
US4031231A (en) * 1974-06-13 1977-06-21 Merck & Co., Inc. Antibacterial composition comprising 3-fluoro-D-alanine or deutero analog in combination with auto-antagonist inhibitor
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers

Also Published As

Publication number Publication date
GR3008225T3 (Direct) 1993-09-30
AU624917B2 (en) 1992-06-25
FI901289A7 (fi) 1990-09-16
NO901198D0 (no) 1990-03-14
IE900921L (en) 1990-09-15
CA2010635A1 (en) 1990-09-15
EP0387867B1 (en) 1993-05-05
IE64130B1 (en) 1995-07-12
DE69001503T2 (de) 1993-09-09
CA2010635C (en) 2001-03-06
PT93424A (pt) 1990-11-07
ATE88890T1 (de) 1993-05-15
DE69001503D1 (de) 1993-06-09
NO901198L (no) 1990-09-17
JPH03148221A (ja) 1991-06-25
IL93562A (en) 1996-01-31
IL93562A0 (en) 1990-11-29
AU5073490A (en) 1990-09-20
FI901289A0 (fi) 1990-03-15
EP0387867A1 (en) 1990-09-19
KR900013961A (ko) 1990-10-22
US5061721A (en) 1991-10-29
ES2055197T3 (es) 1994-08-16
DK0387867T3 (da) 1993-06-01
NZ232809A (en) 1992-05-26
PT93424B (pt) 1996-08-30

Similar Documents

Publication Publication Date Title
JP2963720B2 (ja) 記憶および学習憎進または認知もしくは精神障害治療用のｄ―シクロセリンおよびｄ―アラニン含有組成物
AU593051B2 (en) Method of treating alzheimer's disease
US4904681A (en) D-cycloserine and its prodrugs as cognitive enhancers
JP2005527599A (ja) 肥満および摂食障害におけるゾニサミドの使用
JP2003530345A (ja) 急性、慢性疼痛及び／またはニューロパシー性疼痛及び片頭痛の治療のための医薬組成物
JP2015038097A (ja) Ｓ１ｐ受容体アゴニストの投与レジメン
US5260324A (en) Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US20110034565A1 (en) Psycho-pharmaceuticals
JP3832229B2 (ja) フェニルエテンスルホンアミド誘導体含有医薬
JPH08510990A (ja) グリシンｎｍｄａレセプター複合体の機能的アンタゴニストによる認識の改良方法
JPH0157093B2 (Direct)
AU2005300691A1 (en) Combinations of nicotinic acetylcholine alpha 7 receptor agonists
KR20220113411A (ko) KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도
JPH02225412A (ja) グリシンｂを含有する抗精神病用医薬組成物
JPH05132430A (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
JPH02502546A (ja) 抗ひきつけ剤組成物および方法のためのデキストロルファン相乗的協力剤
WO2000050019A2 (de) VERWENDUNG VON R-ARYLPROPIONSÄUREN ZUR HERSTELLUNG VON ARZNEIMITTELN, ZUR BEHANDLUNG VON ERKRANKUNGEN BEI MENSCH UND TIER, WELCHE DURCH DIE HEMMUNG DER AKTIVIERUNG VON NF-λB THERAPEUTISCH BEEINFLUSST WERDEN KÖNNEN
GB2355659A (en) beta-Carboline derivatives for use in treatment of pain, trauma, spasticity and movement disorders
JP2005501108A (ja) 神経変性治療におけるネフィラセタムの使用
US5087633A (en) Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
US5468763A (en) Use of a glycine B partial agonist for memory and learning enhancement or treatment of a cognitive disorder
KR20040020054A (ko) 통증 치료시 중독 예방
WO1996015788A1 (en) Use of amino-isoxazolidone compounds for improvement of implicit memory
CA2416706C (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient
Reddy et al. Pharmacotherapy of Basal Ganglia Disorders: Parkinson Disease and Huntington Disease